{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066969","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.857374+00:00","generated_at":"2026-05-22T05:18:16.357039+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Janux Q1 net loss $23.5M; initiates JANX007 Phase 1b expansion in mCRPC","bullets":["Initiated Phase 1b expansion with JANX007 in taxane-naïve mCRPC; updated median rPFS 7.5 months (n=16).","Cash and equivalents $1.01B at March 31, 2025, down from $1.03B at Dec 31, 2024.","R&D expenses $25.1M (Q1 2025) vs $14.1M (Q1 2024); net loss $23.5M vs $14.8M.","Additional JANX007 and JANX008 data expected in H2 2025; R&D Day planned mid-2025.","Selected two dose regimens (0.3/2/6mg and 0.3/2/9mg) for Phase 1b expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066969","json":"https://secwatch.observer/filing/0000950170-25-066969.json","markdown":"https://secwatch.observer/filing/0000950170-25-066969.md","text":"https://secwatch.observer/filing/0000950170-25-066969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017025066969/0000950170-25-066969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017025066969/janx-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:18:16.357039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}